All In Biotech

Drug Trial Radar · NCT04458051

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 767 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

767

Actual

Start

Aug 13, 2020

Primary completion

Nov 14, 2025

Study completion Nov 14, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168

Conditions

  • Primary Progressive Multiple Sclerosis

Interventions

  • TolebrutinibDrug

    Pharmaceutical form: Film-coated Tablet Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Film-coated Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-month composite Confirmed Disability Progression (cCDP)Time frame: Up to approximately 60 months

Locations

277 sites in 42 countries. Site status is shown where the registry gives one.

  • UC San Diego ACTRI Site Number : 8400101

    La Jolla, California

  • Collaborative Neuroscience Research Site Number : 8400045

    Los Alamitos, California

  • Multiple Sclerosis Center- Site Number : 8400143

    Los Angeles, California

  • Multiple Sclerosis Center of California Site Number : 8400135

    Newport Beach, California

  • SC3 Research - Pasadena Site Number : 8400070

    Pasadena, California

  • University of San Francisco, Sandler Neurosciences Center- Site Number : 8400137

    San Francisco, California

  • Harbor UCLA Site Number : 8400088

    Torrance, California

  • Regina Berkovich, MD, PhD Site Number : 8400059

    West Hollywood, California

  • Advanced Neurosciences Research Site Number : 8400025

    Fort Collins, Colorado

  • South Florida Neurology Associates Site Number : 8400029

    Boca Raton, Florida

  • MS & Neuromuscular Center of Excellence Site Number : 8400172

    Clearwater, Florida

  • University of Florida, Fixel Center for Neurology Site Number : 8400159

    Gainesville, Florida

  • Neurology Associates, PA- Site Number : 8400004

    Maitland, Florida

  • University of South Florida Site Number : 8400006

    Tampa, Florida

  • Velocity Clinical Research Site Number : 8400003

    Savannah, Georgia

  • Hawaii Pacific Neuroscience Site Number : 8400103

    Honolulu, Hawaii

  • Consultants In Neurology- Site Number : 8400011

    Northbrook, Illinois

  • Methodist Hospital Site Number : 8400164

    Merrillville, Indiana

  • College Park Family Care Center Site Number : 8400044

    Overland Park, Kansas

  • University of Kentucky Site Number : 8400106

    Lexington, Kentucky

  • Ochsner Baptist Clinical Trials Unit (CTU)- Site Number : 8400107

    New Orleans, Louisiana

  • International Neurorehabilitation Institute Site Number : 8400034

    Lutherville, Maryland

  • Tufts Medical Center Site Number : 8400072

    Boston, Massachusetts

  • University of Massachusetts Site Number : 8400014

    Worcester, Massachusetts

  • Michigan Institute For Neurological Disorders Site Number : 8400058

    Farmington Hills, Michigan

  • The Memorial Hospital- Site Number : 8400033

    Owosso, Michigan

  • Mayo Clinic Site Number : 8400111

    Rochester, Minnesota

  • Sharlin Health & Neurology Site Number : 8400093

    Ozark, Missouri

  • University Of Nebraska- Site Number : 8400129

    Omaha, Nebraska

  • Hackensack University Hospital Site Number : 8400047

    Hackensack, New Jersey

  • University of New Mexico Site Number : 8400032

    Albuquerque, New Mexico

  • Icahn School of Medicine at Mount Sinai (Department of Endoc Site Number : 8400038

    New York, New York

  • Neurology Associates of Stony Brook Site Number : 8400042

    Stony Brook, New York

  • Duke Neurological Disorders Clinic- Site Number : 8400098

    Durham, North Carolina

  • Meridian Clinical Research, LLC- Site Number : 8400005

    Raleigh, North Carolina

  • Atrium Health Wake Forest Baptist Site Number : 8400116

    Winston-Salem, North Carolina

  • Riverhills Neuroscience - Norwood Site Number : 8400167

    Cincinnati, Ohio

  • Cleveland Clinic Site Number : 8400125

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center- Site Number : 8400150

    Columbus, Ohio

  • The Boster Center for Multiple Sclerosis Site Number : 8400147

    Columbus, Ohio

Showing 40 of 277 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.